Smith+Nephew expands CARTIHEAL AGILI-C launch to 12 European markets

Expanded commercial launch of CARTIHEAL AGILI-C implant to 12 European markets. New markets added include Germany, Ireland, Italy, and Luxembourg. Clinical trial data shows superior pain relief and functional gains over 5 years. Product utilizes aragonite material for biphasic cartilage and bone regeneration.

Smith+Nephew to showcase shoulder repair tech at ICSES 2026

Smith+Nephew highlights TENDON SEAM, REGENETEN, and Q-FIX KNOTLESS 2.8 at ICSES 2026. TENDON SEAM shows 2X increase in repair strength vs traditional techniques. REGENETEN implant linked to halved early recovery time for partial-thickness tears. CORI SHOULDER handheld robotics launched for anatomic and reverse arthroplasty.

Smith+Nephew buys back $250m of 2030 notes in oversubscribed tender

Smith+Nephew accepted U.S.$250 million of its 2.032% senior notes due 2030 in a cash tender offer. The offer was oversubscribed with U.S.$431.8 million tendered, leading to a 57.995% scaling factor. Holders received U.S.$878.90 per U.S.$1,000 principal amount for accepted notes. Settlement is expected on September 18, 2026, with purchased notes to be canceled.

Tampa General performs world-first surgery using new EVOS pelvic system

Tampa General and FOI performed the world's first surgery using the EVOS Pelvic and Acetabular System in August 2026. Dr. Hassan Mir, a co-designer of the system with Smith+Nephew, led the procedure at Tampa General. The FDA-cleared system aims to streamline complex pelvic fracture repairs and reduce operating room time. Broader availability across US hospitals is expected following this initial clinical milestone.

Smith+Nephew, Imperial launch five-year surgical robotics centre

Smith+Nephew and Imperial College London have launched a five-year partnership to create a university technology centre for robotic surgery. The initiative focuses on markerless tracking and real-time computer vision to make procedures less invasive. This marks Smith+Nephew's first university-founded centre and Imperial's first medtech industry centre, aiming to accelerate clinical translation of academic research.

Smith & Nephew Lowers FY26 Sales Guidance to $6B

Smith & Nephew reduces its FY2026 sales guidance from $6 billion to $6 billion. This revised outlook is compared against a $1.602 billion estimate. The move reflects updated expectations for the medical device firm's performance.